<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642262</url>
  </required_header>
  <id_info>
    <org_study_id>2013-MUC-02</org_study_id>
    <nct_id>NCT03642262</nct_id>
  </id_info>
  <brief_title>Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h</brief_title>
  <official_title>A Phase I, Open-label, Single Dose, Randomized, 2-way Crossover Bioequivalence Study Comparing Mucinex® Extended Release 600 mg Bi-Layer Tablet to a Reference Immediate Release Guaifenesin Tablet (Taken as 200 mg Every 4 Hours [q4h] x 3 Doses) in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate bioequivalence of guaifenesin in Mucinex® extended release (ER) 600 mg tablet in
      normal healthy volunteers compared to the immediate release guaifenesin 200 mg tablet
      reference product marketed
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2013</start_date>
  <completion_date type="Actual">August 9, 2013</completion_date>
  <primary_completion_date type="Actual">August 9, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2-Way Crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>Maximum measured analyte concentration over the sampling period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>Time of the maximum measured analyte concentration over the sampling period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>AUCinf = AUCt + Cp/Kel, where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (Kel) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least squares regression of log (concentration) versus time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T½) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>Terminal elimination half-life, calculated from the equation: T½ = In(2)/Kel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability (RF) of Guaifenesin</measure>
    <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
    <description>RF is measured by (AUCinf ER / AUCinf IR) x (ER dose / IR dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events(AEs) Experienced by Participants</measure>
    <time_frame>Up to period 2 (8.3 days/200 hours)</time_frame>
    <description>Intensity determination Mild=AE does not limit usual activities; subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present (causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight, but remote, chance that the AE was caused by study drug, but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug Investigational Medicinal Product (IMP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A: Mucinex® ER 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Guaifenesin 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucinex®</intervention_name>
    <description>Mucinex® 600 mg single dose ER bi-layer tablet</description>
    <arm_group_label>Treatment A: Mucinex® ER 600 mg</arm_group_label>
    <arm_group_label>Treatment B: Guaifenesin 200 mg</arm_group_label>
    <other_name>guaifenesin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent has been obtained (i.e. be informed of the nature of the study and
             give written consent prior to any study procedure). Able to read, understand, and sign
             the informed consent, after the nature of the study has been explained.

          2. Age: 18 to 55 years of age, inclusive.

          3. Sex: Male or female.

          4. Status: Healthy subjects.

          5. BMI: ≥18.0 and ≤28.0 kg/m2.

          6. No clinically significant findings in vital signs measurements at screening.

          7. No clinically significant abnormal laboratory values at screening.

          8. No clinically significant findings from a 12-lead electrocardiogram (ECG) at
             screening.

          9. Have no significant diseases or clinically relevant medical condition in the opinion
             of the investigator.

         10. Males who participate in this study are willing to:

               -  remain abstinent [not engage in sexual intercourse] from the start of drug
                  administration until 90 days after the end of the study or

               -  use (or their partner will use, as applicable) two effective methods of birth
                  control [condom, diaphragm, cervical cap, vaginal sponge, spermicide, IUD, tubal
                  ligation, vasectomy, or hormonal contraceptives] from the start of drug
                  administration until 90 days after the end of the study.

             Females who participate in this study are:

               -  unable to have children (e.g., post-menopausal, hysterectomy);

               -  willing to remain abstinent [not engage in sexual intercourse] from 21 days prior
                  to drug administration until 30 days after the end of the study; or

               -  willing to use two effective methods of birth control [condom, diaphragm,
                  cervical cap, vaginal sponge, spermicide, non-hormonal Intrauterine Device (IUD)
                  (in place for 3 months), tubal ligation, partner has vasectomy, hormonal
                  contraceptives for 3 months prior to drug administration] from 30 days prior to
                  drug administration until 30 days after the end of the study.

         11. Have no clinically significant findings from a physical examination.

        Exclusion Criteria:

        Subjects to whom any of the following conditions apply must be excluded:

          1. Employee of Pharma Medica Research Inc. (PMRI) or Reckitt Benckiser.

          2. Partner or first-degree relative of any Investigator at PMRI.

          3. Known history or presence of any clinically significant medical condition.

          4. Known or suspected carcinoma.

          5. Presence of hepatic or renal dysfunction.

          6. Presence of clinically significant gastrointestinal disease or history of
             malabsorption within the last year.

          7. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase
             insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose
             malabsorption syndrome.

          8. Presence of a medical condition requiring regular medication (prescription and/or
             over-the-counter) with systemic absorption.

          9. History of drug or alcohol or medicinal product addiction requiring treatment within
             the past two years or excessive alcohol consumption (more than 10 units per week)
             Note: one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of
             spirits

         10. Positive test result for serum Human Chorionic Gonadotropin (hCG) consistent with
             pregnancy (females only), HIV, Hepatitis B surface antigen or Hepatitis C antibody.

         11. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines,
             cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and
             benzodiazepines) or urine cotinine.

         12. Difficulty fasting or consuming standard meals.

         13. Females who are lactating.

         14. Does not tolerate venipuncture.

         15. Use of tobacco or nicotine-containing products within 12 months prior to drug
             administration.

         16. On a special diet within 30 days prior to drug administration (e.g., liquid, protein,
             raw, food diet).

         17. Donation or loss of whole blood (including clinical trials):

               -  ≥50 ml and ≤499 ml within 30 days prior to drug administration

               -  ≥500 ml within 56 days prior to drug administration.

         18. Females who have started taking hormonal contraceptives or have changed their method
             or brand of hormonal birth control within 3 months prior to drug administration.

         19. Have had a tattoo or body piercing within 30 days prior to drug administration.

         20. Use of drugs of the monoamine oxidase inhibitor (MAOI) class within 30 days prior to
             drug administration.

         21. Known history or presence of hypersensitivity, intolerance or idiosyncratic reaction
             to guaifenesin or any other drug substances with similar activity.

         22. Previously enrolled in this study.

         23. Participated in another clinical trial or received an investigational product within
             30 days prior to drug administration.

         24. Unable in the opinion of the Investigator to comply fully with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <results_first_submitted>October 8, 2018</results_first_submitted>
  <results_first_submitted_qc>March 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2019</results_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-centre study conducted in Canada.</recruitment_details>
      <pre_assignment_details>Total Thirty (30) subjects were enrolled in the study among them 27 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (Mucinex First Then Guaifenesin)</title>
          <description>Treatment A : Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
Treatment B : Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.
Cohort 1
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug administrations.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 (Guaifenesin Then Mucinex)</title>
          <description>Treatment A : Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
Treatment B : Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.
Cohort 2
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug administrations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout: 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Treatment A : Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
Treatment B : Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.
Cohort 1
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug administrations.
Cohort 2
Period 1 - Treatment A or Treatment B at Sequence AB.
Period 2 - Treatment B or Treatment A at Sequence BA.
Scheduled Washout of 7 days between drug administrations.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age Group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
        <description>Maximum measured analyte concentration over the sampling period.</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>Pharmacokinetic (PK) Parameter Set Population includes all subjects from the PK dataset with evaluable PK parameters for each treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</title>
          <description>Maximum measured analyte concentration over the sampling period.</description>
          <population>Pharmacokinetic (PK) Parameter Set Population includes all subjects from the PK dataset with evaluable PK parameters for each treatment period.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1076.37" spread="414.80"/>
                    <measurement group_id="O2" value="1223.89" spread="522.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Guaifenesin</title>
        <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>PK Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Guaifenesin</title>
          <description>The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.</description>
          <population>PK Dataset</population>
          <units>ng·h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4288.30" spread="1654.57"/>
                    <measurement group_id="O2" value="4641.48" spread="2211.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</title>
        <description>Time of the maximum measured analyte concentration over the sampling period.</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>PK Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</title>
          <description>Time of the maximum measured analyte concentration over the sampling period.</description>
          <population>PK Dataset</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.33"/>
                    <measurement group_id="O2" value="1.45" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</title>
        <description>AUCinf = AUCt + Cp/Kel, where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>PK Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</title>
          <description>AUCinf = AUCt + Cp/Kel, where Cp is the predicted analyte concentration at the time of the last measurable analyte concentration.</description>
          <population>PK Dataset</population>
          <units>ng·h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4306.21" spread="1658.06"/>
                    <measurement group_id="O2" value="4647.47" spread="2212.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
        <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least squares regression of log (concentration) versus time</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>PK Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (Kel) of Guaifenesin</title>
          <description>Elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least squares regression of log (concentration) versus time</description>
          <population>PK Dataset</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4727" spread="0.1711"/>
                    <measurement group_id="O2" value="0.7635" spread="0.1011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (T½) of Guaifenesin</title>
        <description>Terminal elimination half-life, calculated from the equation: T½ = In(2)/Kel.</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>PK Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T½) of Guaifenesin</title>
          <description>Terminal elimination half-life, calculated from the equation: T½ = In(2)/Kel.</description>
          <population>PK Dataset</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.75"/>
                    <measurement group_id="O2" value="0.93" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Bioavailability (RF) of Guaifenesin</title>
        <description>RF is measured by (AUCinf ER / AUCinf IR) x (ER dose / IR dose)</description>
        <time_frame>0 (pre-dose) ,0.25,0.5, 0.75, 1,1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14, 16, 20 and 24 hours</time_frame>
        <population>Outcome involved analyzing data from both intervention groups (ER and IR) in combination as per the provided formula, therefore, separate analysis for each intervention cannot be reported</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (RF) of Guaifenesin</title>
          <description>RF is measured by (AUCinf ER / AUCinf IR) x (ER dose / IR dose)</description>
          <population>Outcome involved analyzing data from both intervention groups (ER and IR) in combination as per the provided formula, therefore, separate analysis for each intervention cannot be reported</population>
          <units>ng·h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9542" spread="0.1770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events(AEs) Experienced by Participants</title>
        <description>Intensity determination Mild=AE does not limit usual activities; subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present (causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight, but remote, chance that the AE was caused by study drug, but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug Investigational Medicinal Product (IMP)</description>
        <time_frame>Up to period 2 (8.3 days/200 hours)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Mucinex® ER 600 mg</title>
            <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
          </group>
          <group group_id="O2">
            <title>Reference: Guaifenesin 200 mg</title>
            <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events(AEs) Experienced by Participants</title>
          <description>Intensity determination Mild=AE does not limit usual activities; subject may experience slight discomfort Moderate=AE results in some limitation of usual activities;subject may experience significant discomfort Severe=AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain Unassessable/Unclassifiable=Insufficient information to be able to make an assessment Conditional/Unclassified=Insufficient information to make an assessment at present (causality is conditional on additional information) Unrelated=No possibility that the AE was caused by study drug Unlikely=Slight, but remote, chance that the AE was caused by study drug, but the balance of judgment is that it was most likely not due to the study drug Possible=Reasonable suspicion that the AE was caused by the study drug Probable=Most likely that the AE was caused by study drug Certain=The AE was definitely caused by study drug Investigational Medicinal Product (IMP)</description>
          <population>Safety population</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE by severity: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE by severity: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unassessable/Unclassifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Conditional /Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP: Certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8.3 days (200 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Mucinex® ER 600 mg</title>
          <description>Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: Guaifenesin 200 mg</title>
          <description>Guaifenesin 200 mg immediate release (IR) tablet q4h (total of 3 doses) by mouth under fasting condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser Inc.</organization>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

